The emergence of new biologics for severe asthma
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 46, 108-115
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- GSK
- Novartis
- Teva
This publication has 69 references indexed in Scilit:
- A Large Subgroup of Mild-to-Moderate Asthma Is Persistently NoneosinophilicAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161Nature Immunology, 2011
- Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trialEuropean Respiratory Journal, 2010
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Mepolizumab and Exacerbations of Refractory Eosinophilic AsthmaNew England Journal of Medicine, 2009
- Determining asthma treatment by monitoring sputum cell counts: effect on exacerbationsEuropean Respiratory Journal, 2006
- Inflammatory subtypes in asthma: Assessment and identification using induced sputumRespirology, 2006
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Eosinophilic Inflammation in AsthmaNew England Journal of Medicine, 1990